国产亚洲精品VA片在线播放,色五月在线观看

您好，歡迎來到拜力生物網(wǎng)站！請登錄注冊

我的訂單 | 聯(lián)系我們 | 在線客服QQ：3012681483 | 客服電話：400-968-7988 | 工作時間：08:30-17:30

主營產(chǎn)品： ELISA試劑盒、抗體、補體血清、兔補體、干擾素、小鼠測溫儀、進口試劑、Quidel代理、Swant代理、PBL Assay Science代理

網(wǎng)站首頁產(chǎn)品中心代理品牌新聞資訊資源中心關于我們

所在位置：首頁 > 產(chǎn)品中心 > Antibodies > Antibodies產(chǎn)品

訂購信息

上海拜力生物科技公司

Tel:400-968-7988 021-33779008

Anti-Von-Willebrand-Factor Antibody

品牌：Antibodies

貨號：

規(guī)格：5ml

貨期：

應用：

咨詢客服

立即購買加入購物車

Anti-Von-Willebrand-Factor Antibody

商品詳情參考文獻相關資料

Overview

Name:	Anti-Von-Willebrand-Factor Antibody See all Von Willebrand Factor primary antibodies
Description:	Mouse monoclonal (F8/86) antibody to Von-Willebrand-Factor.
Specificity:	Human von-Willebrand-Factor, Factor VIII related Antigen.
Applications:	IHC
Reactivity:	Human
Immunogen:	Purified von-Willebrand-Factor isolated from human plasma.
Host:	Mouse
Clonality:	Monoclonal
Clone:	F8/86
Isotype:	IgG1
Conjugate:	Unconjugated
Product Form:	Liquid
Formulation:	Supplied in Phosphate Buffered Saline, pH 7.3, with 0.09% Sodium Azide.
Storage:	Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
General Notes:	This antibody detects normal endothelia, megakaryocytes and platelets, but also tumours derived from these cells. It is a good marker for vascularisation of tissues and re-vascularisation after injury. This antibody may also be used for the detection of tumour invasion into blood vessels.

Target

Function:	Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Tissue Specificity:	Plasma.
Involvement in Disease:	von Willebrand disease 1: A common hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 1 is characterized by partial quantitative deficiency of circulating von Willebrand factor, that is otherwise structurally and functionally normal. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. von Willebrand disease 2: A hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in altered platelet aggregation. Von Willebrand disease type 2 is characterized by qualitative deficiency and functional anomalies of von Willebrand factor. It is divided in different subtypes including 2A, 2B, 2M and 2N (Normandy variant). The mutant VWF protein in types 2A, 2B and 2M are defective in their platelet-dependent function, whereas the mutant protein in type 2N is defective in its ability to bind factor VIII. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. von Willebrand disease 3: A severe hemorrhagic disorder due to a total or near total absence of von Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. Bleeding usually starts in infancy and can include epistaxis, recurrent mucocutaneous bleeding, excessive bleeding after minor trauma, and hemarthroses.
Post-Translational Modification:	All cysteine residues are involved in intrachain or interchain disulfide bonds.
Cellular Location:	Secreted. Secreted > Extracellular space > Extracellular matrix. Localized to storage granules.
Database Links:	Entrez Gene: 7450?Human Omim: 613160?Human SwissProt: P04275?Human Unigene: 440848?Human
Synonyms:	Coagulation factor VIII Antibody Coagulation factor VIII VWF Antibody F8VWF Antibody Factor VIII related antigen Antibody von Willebrand antigen 2 Antibody von Willebrand antigen II Antibody Von Willebrand disease Antibody Von Willebrand Factor Antibody VWD Antibody vWF Antibody VWF_HUMAN Antibody
Information:	Target information shown above is from the UniProt Consortium.